Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
Bausch Health and its Salix Pharmaceuticals GI business announced results from a six-month, five-practice pilot study of a standardized cirrhosis clinical pathway, presented at the ACG annual meeting. Across 4,251 patients, adherence metrics improved modestly, including office visit adherence up from 46.9% to 51.1% and hepatic encephalopathy treatment rates up from 60.2% to 64.9%.
Key figures
- Practices count
- 5
- Patients analyzed
- 4251
- He treatment rates
- 60.2% to 64.9% (7.8% relative improvement)
- Pilot duration months
- 6
- Office visit adherence
- 46.9% to 51.1% (9.0% relative improvement)
- Beta blocker use varices
- 47.2% to 48.8% (3.4% relative improvement)
- Lab monitoring adherence
- 61.5% to 63.5% (3.2% relative improvement)
- Chronic care management enrollment
- 11.7% to 12.8% (9.4% relative improvement)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.